SCHEMBL6115201

SCHEMBL6115201

Cc1cccc2[nH]cc(Cc3nn(CC(=O)NS(C)(=O)=O)c(=O)c4ccccc34)c12

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CMA1 P23946 5/20 0.54
▸ TSHR P16473 1/20 0.44
▸ RAB9A P51151 1/20 0.43
▸ GPR84 Q9NQS5 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ AKR1B1 P15121 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18900943 0.87 CMA1 (0.53) CMA1TSHRRAB9AGPR84ALOX15
SCHEMBL18900819 0.86 CMA1 (0.52) CMA1TSHRRAB9AGPR84ALOX15
SCHEMBL18900860 0.85 CMA1 (0.52) CMA1TSHRRAB9AGPR84ALOX15
SCHEMBL18900696 0.84 CMA1 (0.52) CMA1TSHRRAB9AGPR84ALOX15
SCHEMBL18900859 0.82 GPR84 (0.52) CMA1TSHRGPR84ALOX15CYP1A2
SCHEMBL7963167 0.81 CMA1 (0.49) CMA1TSHRRAB9AGPR84ALOX15
SCHEMBL18900945 0.81 CMA1 (0.53) CMA1TSHRRAB9AGPR84ALOX15
SCHEMBL7960283 0.76 CMA1 (0.65) CMA1TSHRGPR84ALOX15CYP1A2
SCHEMBL7965706 0.75 CMA1 (0.44) CMA1TSHRGPR84CYP1A2CYP3A4
SCHEMBL7950640 0.75 CMA1 (0.44) CMA1TSHRGPR84ALOX15CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323991-B1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2017-05-31 — — EP disclosed
EP-2323991-B1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2017-05-31 — — EP disclosed
US-8969348-B2 Chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-03-03 — — US disclosed
US-8969348-B2 Chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-03-03 — — US disclosed
US-20120129863-A1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-24 — — US disclosed
US-20120129863-A1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-24 — — US disclosed
WO-2010019417-A2 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129863-A1 CHYMASE INHIBITORS CMA1, CPA3, SERPINB1 CMA1 1/4885TSHR 4225/4885RAB9A 1439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback